A new study has found that a drop in serum inorganic phosphate (iP) was an early predictor of severe cytokine release syndrome (CRS), suggesting that monitoring serum iP levels could help promote ...

Tenapanor significantly reduced elevations in serum phosphate levels of patients undergoing maintenance dialysis for end-stage renal disease (ESRD) and was associated with infrequent adverse events in ...

Elevated serum phosphate levels were associated with an increased fracture risk among older men. High-normal serum phosphate levels are a risk factor for fracture risk among older men, according to ...

Please provide your email address to receive an email when new articles are posted on . Nutritional intervention helped to stabilize serum phosphorus levels. Patients also demonstrated improved ...

Renal transplant patients with elevated phosphorus had lower Hb levels. Higher serum phosphorus levels are associated with lower blood hemoglobin (Hb) levels and a greater likelihood of anemia in ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Compared with patients in European countries and Japan, ...

A group of FDA advisors recommended approval of tenapanor (Ibsrela) for the control of serum phosphorus levels in adults with chronic kidney disease (CKD) on dialysis, both as a single agent and in ...

Excessive phosphate loading within the proximal tubular lumen has been proposed as a key mechanism driving progression of chronic kidney disease (CKD) through calcium phosphate microcrystallopathy.

ISTANBUL, Turkey — The investigational drug PA21 controls hyperphosphatemia over the long term and has a lower pill burden than sevelamer carbonate, according to a phase 3 study. The cardiovascular ...

Sevelamer carbonate 800 mg; tabs. Patients with CKD can develop hyperphosphatemia as a result of retained phosphorus, which may lead to ectopic calcification. Hyperphosphatemia plays a role in the ...